Introduction To CD28
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD28 protein is a common target in medicine.
CD28 is a type I transmembrane protein with an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain of CD28 contains two immunoglobulin-like domains that are responsible for the binding to the ligands CD80 and CD86. CD28 is a costimulatory molecule expressed on the surface of T lymphocytes and plays a key role in the activation of T cells.
Function of Target CD28
CD28 binds to its ligands B7-1 (CD80) and B7-2 (CD86) to provide a costimulatory signal that is required for complete activation of the T cell. The costimulatory signal and antigen stimulation signal (the first signal) cooperate to promote the activation, proliferation, and function of T cells. CD28 is involved in the negative regulation of TCR signaling and can relieve this inhibitory effect by promoting the ubiquitination and subsequent protein degradation of CBL-B, thereby enhancing T-cell activation. Activation of CD28 enhances metabolic pathways in T cells, specifically facilitating glycolytic processes, which provide T cells with rapid energy and biosynthetic precursors to support their activation and proliferation. CD28 signaling increased the expression of surface glucose transporters such as GLUT 1 on the T cells, thus enhancing the glucose uptake capacity of the T cells. CD28 signaling is also involved in the regulation of mitochondrial metabolism, including oxidative phosphorylation and fatty acid oxidation, and these pathways play a key role in long-term T cell survival and function. In the tumor microenvironment, CD28 signaling helps T cells adapt to metabolic stresses, such as low oxygen and nutrient deficiency, thereby maintaining their antitumor activity.
Gene Pathway of Target CD28
Complete activation of initial T cells normally requires three signals. The binding of CD28 to B7 triggers a complex signal transduction cascade, including phosphorylation of tyrosine kinases, recruitment, and activation of intracellular signaling molecules. These signaling events ultimately lead to enhanced T-cell activation, proliferation, and function. In tumor immunotherapy, the anti-tumor immune response of T cells can be enhanced by activating the CD28 signaling pathway. CTLA-4 is a negative regulator of CD28 that competes with CD28 for binding to the B7 molecule and inhibits T-cell activation. Therefore, the effects of CD28 signaling can also be enhanced indirectly, by blocking CTLA-4.

Fig 1: CD28 Gene Pathway. (Reference source: Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 May 17;44(5):973-88. doi: 10.1016/j.immuni.2016.04.020. PMID: 27192564; PMCID: PMC4932896.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD28 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD28 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD28 protein products are also essential. Alpha Lifetech can provide CD28 with corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64650 | 50ug,100ug,500ug | |
| ALP64644 | 50ug,100ug,500ug | |
| ALP64560 | 50ug,100ug,500ug | |
| ALP64537 | 50ug,100ug,500ug | |
| ALP64506 | 50ug,100ug,500ug | |
| ADT1374 | 1mg,5mg | |
| ADT1043 | 1mg,5mg | |
Reference
[1] Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 May 17;44(5):973-88.
[2] Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, Vale RD. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017 Mar 31;355(6332):1428-1433.
[3] Xia S, Chen Q, Niu B. CD28: A New Drug Target for Immune Disease. Curr Drug Targets. 2020;21(6):589-598.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
0102




2018-07-16


